A Phase 1 interventional study of BIO 300 Oral Powder in Acute Radiation Syndrome, sponsored by Humanetics Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-03.
Sponsored by Humanetics Corporation · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.
Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At the discretion of the Investigator, blood routine, liver and kidney functions are within the controllable range.
Exclusion Criteria:
Subjects with any of the following are not eligible;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mg BIO 300 Oral Powder administered as a single dose
Drug: BIO 300 Oral Powder
1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
Drug: BIO 300 Oral Powder
2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
Drug: BIO 300 Oral Powder
Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3
Drug: BIO 300 Oral Powder
Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days
Drug: BIO 300 Oral Powder
Amorphous solid dispersion of genistein milled into a powder
Also known as: BIO 300, Genistein
Adverse Events Related to BIO 300 Oral Powder
Evaluate the safety of single and multiple dose BIO 300 Oral Powder administration
Time frame: Day 1 up to 1 week for Single Ascending Dose and Day 1 up to 2 weeks for Multiple Single Dose
Change in ECG QTc Interval
Measurement of the average QTc interval with Fridericia's correction (completed in triplicate at each timepoint)
Time frame: Day 1 up to 1 week after the last dose for Single Ascending Dose and Multiple Single Dose Cohorts
Change in Clinical Laboratory Values
Monitoring of blood serum levels of albumin and total protein (all reported as g/dL)
Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Change in Clinical Laboratory Values
Monitoring of blood serum levels of bicarbonate, chloride, potassium, and sodium (all reported as mEq/L)
Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Change in Clinical Laboratory Values
Monitoring of blood serum levels of bilirubin (total and direct), BUN, calcium, cholesterol (total), creatinine, HDL, glucose, magnesium, phosphorous, triglycerides, and uric acid (all reported as mg/dL)
Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Change in Clinical Laboratory Values
Monitoring of blood serum levels of alkaline phosphatase, ALT, amylase, AST, LDH, and lipase (all reported as IU/L)
Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Area Under Curve of Genistein-Aglycone in Serum
Area under the curve of BIO 300 Oral Powder as assessed by analyzing serum concentrations of genistein-aglycone (free genistein) at multiple timepoints
Time frame: Day 1 for the Single Ascending Dose and Day 6 for the Multiple Single Dose, prior to 1st dose then 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post dose and Day 1 Multiple Single Dose prior to dosing then 0.5, 1, 2, and 4 hours post dose
Number of Differentially Expressed Genes From Whole Blood Samples
The number of significantly differentially expressed genes detected in whole blood samples at various timepoints after BIO 300 Oral Powder dosing. Significant differential gene expression was defined as genes that have a mean absolute log2 fold change \>2 with an adjusted p-value of \<0.05 relative to baseline expression levels.
Time frame: Day 1 for the Single Ascending Dose prior to dosing then 1, 2, 4, and 24 hours post dose and Day 1 Multiple Single Dose prior to dosing then 1, 2, and 4 hours post dose and and Day 6 prior to dosing then 4, 8, 12 and 24 hours post dose
| Milestone | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 10 |
| Completed | 6 | 6 | 5 | 6 | 8 |
| Not completed | 0 | 0 | 1 | 0 | 2 |
Evaluate the safety of single and multiple dose BIO 300 Oral Powder administration
| Number of Adverse Events | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Dose Limiting Toxicities | — | 0 | 0 | 0 | 0 |
| Unlikely Treatment-Related Adverse Events | — | 1 | 0 | 0 | 2 |
| Possibly Treatment-Related Adverse Events | — | 0 | 0 | 3 | 7 |
| Probably Treatment-Related Adverse Events | — | 4 | 4 | 0 | 15 |
| Definitely Treatment-Related Adverse Events | — | 0 | 0 | 2 | 1 |
| Unrelated Adverse Event | — | 0 | 0 | 1 | 1 |
Measurement of the average QTc interval with Fridericia's correction (completed in triplicate at each timepoint)
| milliseconds | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Screening | 407 ± 9.3 | 402 ± 19.3 | 416 ± 21.8 | 415 ± 18.7 | 413 ± 13.3 |
| 4 Hours Post First Dose | 412 ± 9.6 | 407 ± 16.5 | 419 ± 27.8 | 420 ± 16.3 | 417 ± 7.4 |
| 24 Hours Post First Dose | 407 ± 11.3 | 400 ± 11.2 | 402 ± 26.7 | 404 ± 41.7 | 413 ± 9.9 |
| 1 Week Post Last Dose | 408 ± 12.4 | 401 ± 18.3 | 416 ± 36.3 | 414 ± 12.6 | 415 ± 9.0 |
Monitoring of blood serum levels of albumin and total protein (all reported as g/dL)
| g/dL | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Albumin Day 3 | 4.483 ± 0.204 | 4.433 ± 0.393 | 4.333 ± 0.367 | 4.550 ± 0.187 | 4.225 ± 0.349 |
| Albumin Day 6 | — | — | — | — | 4.475 ± 0.249 |
| Albumin Day 7 | 4.233 ± 0.216 | 4.283 ± 0.279 | 4.440 ± 0.241 | 4.517 ± 0.117 | — |
| Albumin Day 13 | — | — | — | — | 4.475 ± 0.306 |
| Total Protein Day 3 | 6.667 ± 0.344 | 6.833 ± 0.638 | 6.500 ± 0.369 | 6.650 ± 0.547 | 6.363 ± 0.444 |
| Total Protein Day 6 | — | — | — | — | 6.788 ± 0.348 |
| Total Protein Day 7 | 6.417 ± 0.331 | 6.850 ± 0.619 | 6.520 ± 0.438 | 6.717 ± 0.454 | — |
| Total Protein Day 13 | — | — | — | — | 6.550 ± 0.518 |
Monitoring of blood serum levels of bicarbonate, chloride, potassium, and sodium (all reported as mEq/L)
| mEq/L | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Bicarbonate Day 3 | 26.833 ± 1.722 | 26.167 ± 0.753 | 27.167 ± 2.401 | 27.500 ± 1.049 | 23.875 ± 2.850 |
| Bicarbonate Day 6 | — | — | — | — | 23.750 ± 1.165 |
| Bicarbonate Day 7 | 26.500 ± 1.871 | 27.500 ± 1.761 | 29.000 ± 0.707 | 28.667 ± 1.751 | — |
| Bicarbonate Day 13 | — | — | — | — | 23.125 ± 1.246 |
| Chloride Day 3 | 104.5 ± 2.429 | 104.0 ± 1.549 | 104.7 ± 0.816 | 103.5 ± 0.837 | 105.5 ± 1.927 |
| Chloride Day 6 | — | — | — | — | 103.8 ± 2.252 |
| Chloride Day 7 | 104.3 ± 1.366 | 104.5 ± 1.761 | 104.2 ± 1.095 | 104.8 ± 2.317 | — |
| Chloride Day 13 | — | — | — | — | 105.1 ± 0.835 |
| Potassium Day 3 | 4.417 ± 0.271 | 4.500 ± 0.141 | 4.617 ± 0.306 | 4.400 ± 0.303 | 4.288 ± 0.318 |
| Potassium Day 6 | — | — | — | — | 4.413 ± 0.336 |
| Potassium Day 7 | 4.217 ± 0.279 | 4.483 ± 0.306 | 4.580 ± 0.460 | 4.233 ± 0.151 | — |
| Potassium Day 13 | — | — | — | — | 4.288 ± 0.155 |
| Sodium Day 3 | 140.7 ± 1.966 | 139.5 ± 1.225 | 140.7 ± 0.816 | 140.2 ± 1.835 | 140.0 ± 1.414 |
| Sodium Day 6 | — | — | — | — | 139.5 ± 1.414 |
| Sodium Day 7 | 140.0 ± 1.265 | 139.2 ± 1.472 | 139.2 ± 1.304 | 142.3 ± 2.066 | — |
| Sodium Day 13 | — | — | — | — | 140.1 ± 1.727 |
Monitoring of blood serum levels of bilirubin (total and direct), BUN, calcium, cholesterol (total), creatinine, HDL, glucose, magnesium, phosphorous, triglycerides, and uric acid (all reported as mg/dL)
| mg/dL | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Total Bilirubin Day 3 | 0.467 ± 0.308 | 0.417 ± 0.117 | 0.333 ± 0.137 | 0.650 ± 0.501 | 0.613 ± 0.394 |
| Total Bilirubin Day 6 | — | — | — | — | 0.500 ± 0.185 |
| Total Bilirubin Day 7 | 0.483 ± 0.331 | 0.583 ± 0.417 | 0.340 ± 0.167 | 0.400 ± 0.141 | — |
| Total Bilirubin Day 13 | — | — | — | — | 0.563 ± 0.307 |
| Direct Bilirubin Day 3 | 0.200 ± 0 | 0.200 ± 0 | 0.200 ± 0 | 0.200 ± 0 | 0.200 ± 0 |
| Direct Bilirubin Day 6 | — | — | — | — | 0.200 ± 0 |
| Direct Bilirubin Day 7 | 0.200 ± 0 | 0.200 ± 0 | 0.200 ± 0 | 0.200 ± 0 | — |
| Direct Bilirubin Day 13 | — | — | — | — | 0.200 ± 0 |
| BUN Day 3 | 18.00 ± 3.46 | 13.33 ± 2.94 | 14.83 ± 4.62 | 13.50 ± 4.51 | 11.88 ± 3.09 |
| BUN Day 6 | — | — | — | — | 12.00 ± 2.83 |
| BUN Day 7 | 16.67 ± 4.23 | 14.50 ± 2.88 | 14.20 ± 5.85 | 13.83 ± 4.26 | — |
| BUN Day 13 | — | — | — | — | 11.63 ± 3.82 |
| Calcium Day 3 | 9.73 ± 0.37 | 9.38 ± 0.32 | 9.27 ± 0.23 | 9.72 ± 0.33 | 9.25 ± 0.34 |
| Calcium Day 6 | — | — | — | — | 9.60 ± 0.19 |
| Calcium Day 7 | 9.47 ± 0.14 | 9.37 ± 0.26 | 9.18 ± 0.37 | 9.50 ± 0.32 | — |
| Calcium Day 13 | — | — | — | — | 9.36 ± 0.30 |
| Cholesterol Day 3 | 200 ± 43 | 181 ± 23 | 158 ± 19 | 210 ± 44 | 178 ± 23 |
| Cholesterol Day 6 | — | — | — | — | 193 ± 22 |
| Cholesterol Day 7 | 195 ± 34 | 180 ± 33 | 173 ± 32 | 213 ± 49 | — |
| Cholesterol Day 13 | — | — | — | — | 177 ± 26 |
| Creatinine Day 3 | 0.905 ± 0.182 | 0.943 ± 0.154 | 0.883 ± 0.180 | 0.900 ± 0.127 | 0.944 ± 0.116 |
| Creatinine Day 6 | — | — | — | — | 1.030 ± 0.099 |
| Creatinine Day 7 | 0.873 ± 0.147 | 1.028 ± 0.150 | 0.954 ± 0.212 | 0.980 ± 0.131 | — |
| Creatinine Day 13 | — | — | — | — | 1.043 ± 0.094 |
| HDL Day 3 | 52 ± 11 | 55 ± 15 | 52 ± 10 | 69 ± 21 | 49 ± 14 |
| HDL Day 6 | — | — | — | — | 55 ± 15 |
| HDL Day 7 | 52 ± 9 | 54 ± 16 | 56 ± 9 | 71 ± 23 | — |
| HDL Day 13 | — | — | — | — | 52 ± 17 |
| Glucose Day 3 | 95.2 ± 8.0 | 89.7 ± 7.3 | 90.7 ± 6.5 | 90.2 ± 8.8 | 96.3 ± 5.8 |
| Glucose Day 6 | — | — | — | — | 93.6 ± 5.2 |
| Glucose Day 7 | 101.5 ± 10.0 | 92.3 ± 2.7 | 97.0 ± 12.1 | 105.8 ± 40.8 | — |
| Glucose Day 13 | — | — | — | — | 93.4 ± 4.7 |
| Magnesium Day 3 | 2.10 ± 0.11 | 2.05 ± 0.14 | 2.07 ± 0.12 | 1.90 ± 0.17 | 1.98 ± 0.10 |
| Magnesium Day 6 | — | — | — | — | 2.05 ± 0.17 |
| Magnesium Day 7 | 2.02 ± 0.12 | 2.12 ± 0.10 | 2.06 ± 0.11 | 1.98 ± 0.12 | — |
| Magnesium Day 13 | — | — | — | — | 2.06 ± 0.09 |
| Phosphorous Day 3 | 3.58 ± 0.37 | 3.62 ± 0.45 | 3.75 ± 0.41 | 3.52 ± 0.34 | 3.14 ± 0.36 |
| Phosphorous Day 6 | — | — | — | — | 3.49 ± 0.34 |
| Phosphorous Day 7 | 3.62 ± 0.53 | 3.68 ± 0.42 | 3.70 ± 0.49 | 3.68 ± 0.62 | — |
| Phosphorous Day 13 | — | — | — | — | 0.39 ± 0.54 |
| Triglycerides Day 3 | 80.2 ± 43.3 | 104.2 ± 91.0 | 80.5 ± 37.5 | 85.5 ± 30.6 | 101.9 ± 38.8 |
| Triglycerides Day 6 | — | — | — | — | 98.6 ± 23.3 |
| Triglycerides Day 7 | 71.3 ± 22.1 | 117.3 ± 107.0 | 79.2 ± 44.5 | 80.5 ± 39.7 | — |
| Triglycerides Day 13 | — | — | — | — | 89.8 ± 20.6 |
| Uric Acid Day 3 | 5.25 ± 1.08 | 4.62 ± 1.26 | 4.48 ± 1.16 | 5.07 ± 1.38 | 5.20 ± 1.50 |
| Uric Acid Day 6 | — | — | — | — | 5.21 ± 1.55 |
| Uric Acid Day 7 | 5.13 ± 1.09 | 5.30 ± 1.89 | 4.10 ± 0.73 | 5.08 ± 1.24 | — |
| Uric Acid Day 13 | — | — | — | — | 5.20 ± 1.60 |
Monitoring of blood serum levels of alkaline phosphatase, ALT, amylase, AST, LDH, and lipase (all reported as IU/L)
| IU/L | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| ALP Day 3 | 74.2 ± 18.1 | 66.7 ± 13.9 | 64.2 ± 18.8 | 62.8 ± 21.4 | 59.5 ± 15.5 |
| ALP Day 6 | — | — | — | — | 60.3 ± 16.2 |
| ALP Day 7 | 69.5 ± 14.7 | 69.0 ± 17.3 | 68.0 ± 21.1 | 52.5 ± 29.7 | — |
| ALP Day 13 | — | — | — | — | 59.4 ± 18.6 |
| ALT Day 3 | 18.2 ± 5.7 | 21.2 ± 18.6 | 15.2 ± 3.2 | 16.2 ± 9.5 | 17.6 ± 5.5 |
| ALT Day 6 | — | — | — | — | 18.4 ± 4.1 |
| ALT Day 7 | 16.7 ± 3.9 | 27.8 ± 24.1 | 17.8 ± 6.3 | 16.7 ± 10.7 | — |
| ALT Day 13 | — | — | — | — | 18.1 ± 5.1 |
| Amylase Day 3 | 26.5 ± 8.0 | 32.2 ± 13.7 | 21.8 ± 8.7 | 26.8 ± 8.0 | 28.0 ± 7.9 |
| Amylase Day 6 | — | — | — | — | 32.8 ± 10.1 |
| Amylase Day 7 | 25.8 ± 7.3 | 30.3 ± 13.4 | 22.6 ± 10.1 | 26.8 ± 10.5 | — |
| Amylase Day 13 | — | — | — | — | 29.8 ± 8.8 |
| AST Day 3 | 19.0 ± 3.6 | 19.7 ± 6.0 | 21.2 ± 6.4 | 21.8 ± 6.1 | 17.8 ± 3.7 |
| AST Day 6 | — | — | — | — | 19.6 ± 4.3 |
| AST Day 7 | 19.2 ± 3.7 | 26.3 ± 11.9 | 23.6 ± 10.9 | 22.2 ± 6.1 | — |
| AST Day 13 | — | — | — | — | 18.1 ± 5.1 |
| LDH Day 3 | 170 ± 20 | 147 ± 14 | 152 ± 31 | 171 ± 48 | 158 ± 15 |
| LDH Day 6 | — | — | — | — | 166 ± 19 |
| LDH Day 7 | 171 ± 22 | 157 ± 27 | 161 ± 17 | 179 ± 39 | — |
| LDH Day 13 | — | — | — | — | 173 ± 21 |
| Lipase Day 3 | 26.2 ± 4.9 | 42.8 ± 31.9 | 23.8 ± 10.7 | 33.3 ± 10.6 | 28.6 ± 8.4 |
| Lipase Day 6 | — | — | — | — | 35.5 ± 13.6 |
| Lipase Day 7 | 26.8 ± 3.9 | 35.8 ± 10.5 | 26.6 ± 13.6 | 32.0 ± 13.3 | — |
| Lipase Day 13 | — | — | — | — | 31.4 ± 9.3 |
Area under the curve of BIO 300 Oral Powder as assessed by analyzing serum concentrations of genistein-aglycone (free genistein) at multiple timepoints
| ng/mL*hr | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Area Under Curve of Genistein-Aglycone in Serum | 902.9 ± 605.1 | 1530.9 ± 518.2 | 1730.8 ± 361.6 | 5836.0 ± 3280.8 | 2957.3 ± 1222.4 |
The number of significantly differentially expressed genes detected in whole blood samples at various timepoints after BIO 300 Oral Powder dosing. Significant differential gene expression was defined as genes that have a mean absolute log2 fold change \>2 with an adjusted p-value of \<0.05 relative to baseline expression levels.
| Differentially expressed genes | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| Day 1, 1 hr post-dose | 0 | — | 0 | 0 | 0 |
| Day 1, 2 hr post-dose | 0 | — | 0 | 0 | 0 |
| Day 1, 4 hr post-dose | 0 | — | 1 | 0 | 0 |
| Day 1, 24 hr post-dose | 0 | — | 0 | 0 | 0 |
| Day 6, 4 hr post-dose | 0 | — | 0 | 0 | 0 |
| Day 6, 8 hr post-dose | 0 | — | 0 | 0 | 6 |
| Day 6, 12 hr post-dose | 0 | — | 0 | 0 | 7 |
| Day 6, 24 hr post-dose | 0 | — | 0 | 0 | 0 |
Collected over Screening to 1 week after the last dose of BIO 300 Oral Powder (up to 5 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Ascending Dose Cohort 1 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Single Ascending Dose Cohort 2 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Single Ascending Dose Cohort 3 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Single Ascending Dose Cohort 4 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Multiple Single Dose Cohort 5 | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Event | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 3/6 | 2/6 | 4/6 | 4/10 |
| DiarrheaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 1/6 | 6/10 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 2/6 | 0/6 | 0/10 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 3/10 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 2/10 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/10 |
| Lipase IncreasedInvestigations | 0/6 | 1/6 | 0/6 | 0/6 | 0/10 |
| PalpitationsCardiac disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| Abdominal PainGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| BloatingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| Age, Continuous(years) | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Median | 55 (27 to 59) | 37 (28 to 58) | 40 (22 to 62) | 48 (19 to 63) | 46 (22 to 65) | 45 (19 to 65) |
| Sex: Female, Male(Participants) | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 3 | 3 | 3 | 5 | 18 |
| Male | 2 | 3 | 3 | 3 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 6 | 6 | 6 | 10 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 2 |
| White | 5 | 6 | 5 | 5 | 8 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Single Ascending Dose Cohort 1 | Single Ascending Dose Cohort 2 | Single Ascending Dose Cohort 3 | Single Ascending Dose Cohort 4 | Multiple Single Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 6 | 10 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Jul 2021, 6 months.
Results were first posted in May 2024, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Genistein-based BIO 300
Acute Radiation Syndrome
Humanetics Corporation